Senseonics vs. Tandem: Which Diabetes Stock is a Better Buy?

This post was originally published on this site

Further, the demand for diabetes products continues to rise as cases are spiraling upwards all over the world. According to a report from the World Health Organization, around 422 million worldwide have diabetes and this disease accounts for 1.6 million deaths each year.

Keeping these factors in mind, today I’m going to analyze two diabetes stocks, Senseonics (SENS) and Tandem Diabetes Care (NASDAQ:TNDM), to try and determine which stock is a better buy.

Continue reading on StockNews